Alnylam Pharmaceuticals
ALNY
#634
Rank
โ‚น2.822 T
Marketcap
โ‚น21,806
Share price
0.43%
Change (1 day)
75.48%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚น20.04 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น2.24 Billion. , an increase over its 2023 earnings that were of -โ‚น27.13 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -โ‚น20.46 Billion-24.59%
2023 -โ‚น27.13 Billion-67.84%
2022 -โ‚น84.34 Billion36.93%
2021 -โ‚น61.59 Billion-8.04%
2020 -โ‚น66.98 Billion-15.66%
2019 -โ‚น79.41 Billion12.23%
2018 -โ‚น70.76 Billion62.91%
2017 -โ‚น43.44 Billion17.78%
2016 -โ‚น36.88 Billion43.44%
2015 -โ‚น25.71 Billion60.69%
2014 -โ‚น16 Billion98.2%
2013 -โ‚น8.08 Billion
2011 -โ‚น4.77 Billion27.48%
2010 -โ‚น3.74 Billion-10.92%
2009 -โ‚น4.2 Billion95.77%
2008 -โ‚น2.15 Billion
2006 -โ‚น3.44 Billion-9.13%
2005 -โ‚น3.78 Billion34.74%
2004 -โ‚น2.81 Billion36.79%
2003 -โ‚น2.05 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น52.14 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น415.14 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น11.23 B-154.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น10.24 Billion-49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.6 Billion-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.184 T-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น643.38 B-3,245.35%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น24.5 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel